Combination therapy for treatment of skin diseases
AssigneeSkintech Life Science Limited
InventorMichael C. SCAIFE
Life of this patent
Estimating the term…
Abstract
Described herein are pharmaceutical compositions comprising one or more modulators of a cytochrome 450 enzyme (CYP450) and substituted or unsubstituted diindolylmethane. Also described herein are methods for treating one or more skin conditions by administering a combination therapy comprising substituted or unsubstituted diindolylmethane and one or more modulators of CYP450. In particular, methods are disclosed for improving bioavailability and pharmacokinetic parameters of substituted or unsubstituted diindolylmethane following the combination therapy.
Claims28
A pharmaceutical composition comprising a first component comprising a modulator of a CYP450 enzyme and a second component comprising a substituted or unsubstituted diindolylmethane, wherein said composition is for treating a skin condition.
(canceled)
(canceled)
(canceled)
(canceled)
The pharmaceutical composition of claim 44 9, wherein the first component comprises about 400 mg to about 500 mg of the quercetin.
(canceled)
The pharmaceutical composition of claim 44 14, wherein the second component comprises about 30 mg to about 100 mg of the substituted or unsubstituted diindolylmethane.
20-39. (canceled)
43-45. (canceled)
49-53. (canceled)
Dependencies are inferred from the claim text.